Ainos Inc (AIMD)

Sep 25, 2026

Ainos and BioPhoenix have signed a VELDONA License Agreement, creating a collaboration framework potentially worth $10 million. BioPhoenix will fund and advance the clinical and regulatory development for two initial indications, Sjögren's disease and thrombocytopenia, while Ainos retains platform ownership and commercial interests. This partnership aims to reduce Ainos's capital requirements for development and includes potential future licenses for 15 additional indications and revenue sharing.

Sep 16, 2026

VASRO GmbH has released a research update highlighting Ainos' strengthening commercial momentum for its AI Nose platform in semiconductor applications. Key indicators include the transition of its front-end semiconductor program to initial commercial orders and the expansion of its proprietary real-world chemical dataset beyond one billion records. These developments signify progress in Ainos' commercial adoption and the data foundation supporting its Chemical Intelligence strategy.

Sep 14, 2026

Ainos Inc. (NASDAQ:AIMD) shares increased by 6.9% after the company announced it received initial commercial orders for its AI Nose platform from a semiconductor manufacturer. These orders signify a transition from technical validation to commercial deployment for its chemical sensing technology. The company also reported that its proprietary real-world chemical dataset has surpassed one billion records, enhancing its Chemical Intelligence strategy.